WuXi Biologics Deep Dive: A Biologics CRDMO Where Manufacturing Delivery Runs Ahead While Valuation Is Held Back by a Geopolitical Discount

What the market trades today is really two narratives of almost equal weight pointing in opposite directions. One is the fundamentals narrative: in 2025 WuXi Biologics' earnings leverage clearly came back, and the drivers are clear, namely a better business mix, higher capacity utilization, European capacity beginning to ramp, a rising share of complex modalities such as bispecifics and ADCs, plus efficiency gains from WBS lean management and digitalization. The other is the policy narrative: the BIOSECURE provisions in the U.S. FY2026 NDAA have become law, with OMB to publish a list of "biotechnology companies of concern," and when the U.S. Department of Defense updated its 1260H list on June 8, 2026, it added WuXi AppTec. WuXi Biologics had still not been formally listed as of 2026-06-12, but that cloud has not dispersed; it has merely shifted from "will it land immediately" to "when, and at what scope, will it land." This is why the same company can look more and more like a commercial platform in its financials yet still trade like an event-driven stock carrying a policy discount.

The big swings in the share price over the past few years have largely tracked these two threads. From the IPO through the boom years, the market gave WuXi Biologics a "scarce platform, high growth" valuation; in fact, in 2021 the company was still able to complete a fourth placement at HK$112 per share, raising net proceeds of about RMB 10.899 billion for global capacity expansion, and the 2021 global partner plan's share-price hurdle of HK$97.8 in the annual report also reflects how high the market's imagination of the company's growth curve was at the time. The drawdown that followed was genuinely driven by three variables changing at once: a post-pandemic reset of the revenue mix, a global biotech funding chill that slowed the pace of early-stage programs, and U.S. political scrutiny of China's bio supply chain that wrote a "China CXO discount" into the valuation, rather than the company suddenly losing its technology. By 2025 the financial results had recovered, but the valuation center had not fully recovered with them.

The most important bull-bear divergence today is over "at what discount the capability will be acknowledged by the market," not over "whether the company has the capability." Bulls see a program funnel advancing toward the back end: at the end of 2025 the company supported 74 Phase III programs and 25 commercial programs, and by the end of April 2026 it had further updated to 78 late-stage and 25 CMO programs; two-thirds of current new programs come from the U.S. and Europe, customer retention remains above 95%, and management even disclosed an MOU with a global big pharma covering 16 programs and a potential 10-year, USD 5 billion scale. These signs suggest that, at least up to the research reference date, customers have not systematically pulled out because of policy noise. Bears see the other side: 58.1% of the company's 2025 revenue still came from North America, the U.S. is its largest profit pool; if a subsequent OMB list formally designates WuXi Biologics a BCC, what is directly restricted is federal procurement and funding chains, but commercial customers may also pre-emptively bring on a second or even multiple suppliers for compliance and board-audit reasons. For a company that lives on long-term stickiness and back-end manufacturing returns, this kind of "slow-variable de-risking" deserves more vigilance than a one-time revenue loss.

Looking at fundamentals, competitive landscape, valuation, and expectations positioning, I lean toward classifying WuXi Biologics as a company "in the middle of a valuation re-rating" rather than a pure high-quality growth stock. It already has several key features of a mature platform: a large enough program funnel, back-end manufacturing starting to deliver, decent profit quality, and a healthy balance sheet, with cash and time deposits totaling RMB 14.80 billion at the end of 2025, well above its RMB 1.04 billion borrowing balance. Yet at the same time, it cannot command a "sovereign secure capacity" premium that is essentially immune to geopolitical scrutiny the way Samsung Biologics and Lonza can. As of the research reference date, WuXi Biologics trades at roughly 22x trailing 2025 earnings, clearly below Samsung Biologics' roughly 30x and Lonza's roughly 38x, and closer to the way China CXOs are priced for risk. The root of this discount is that the market wants to see the boundary of the policy risk first, not that the market has failed to see the recovery.

If I had to characterize the company in one line, it is a platform company whose "fundamentals run ahead of policy while valuation is held back by policy," neither a "good company being undervalued" nor a "high-growth myth gone bust." The label it fits best is "in the middle of a valuation re-rating," neither high-quality compounding growth nor a turnaround: the commercial machine has regained its tempo, but the market is only willing to pay a price with a clear safety discount. This judgment means the conclusion later in this report will not be simply optimistic or pessimistic. The real question is, when you buy this company, are you buying manufacturing delivery or policy clarification. As of 2026-06-12, neither of these variables has fully played out.

Company History

WuXi Biologics emerged because, as the global division of labor in pharma outsourcing kept refining, the WuXi group made an organizational choice to carve the large-molecule platform out of the WuXi AppTec system and build it deep on its own, rather than as an independent startup searching for PMF from scratch. The company's predecessor, WuXi AppTec Biologics (Wuxi) Co., Ltd., was founded on May 25, 2010, established by entities within the WuXi AppTec system; its 2017 prospectus defined it as a global open-access integrated biologics platform whose core task is to provide pharma companies and biotechs with one-stop outsourcing services from discovery and development to manufacturing. This starting point is critical, because it explains why WuXi Biologics wrote "take on the full process plus monetize by moving programs back" into its DNA as a business-model design from the very beginning, rather than outsourcing a single process step.

The early industry environment also gave this model room to grow. Around 2010, global big pharma had matured small-molecule outsourcing, but biologics outsourcing was still highly fragmented, and the handoffs among discovery, process development, clinical supply, and commercial manufacturing were not smooth. The gap WuXi Biologics seized was "industrializing the complex biologics development process," not cheap labor. The 2017 prospectus cited Frost & Sullivan data stating that the company ranked No. 5 globally and No. 1 in China by revenue in the global biologics outsourcing services market in 2016; even though this is an old ranking, it remains useful for understanding the company's market positioning early after its IPO: it broke in on the strength of an integrated platform, not on a single link.

The 2017 IPO was the first time WuXi Biologics was truly priced by the capital markets as an independent asset. The company listed on the Main Board of the Hong Kong Stock Exchange on June 13, 2017; the prospectus showed a global offering of 192,982,500 shares with an offer price range of HK$18.60-HK$20.60, and Reuters subsequently reported that the company priced at the top of the range at HK$20.60, raising about HK$3.98 billion, with total share capital of about 1.134 billion shares after listing. On that basis, the story the market gave it at listing was very clear: it was a rare company in the global biologics outsourcing space that could carry early-stage services all the way to commercial manufacturing, not a traditional CRO. What the market initially paid for was precisely this platform story.

I would define the first phase after listing as a "platform validation and global capacity build-out period." This roughly corresponds to 2017 to 2019. The company's core decision was to turn the integrated platform into a system that global customers could verify, audit, and scale up as quickly as possible, rather than chasing short-term profit. In this phase the company expanded its program pool, expanded manufacturing capacity, and built complex-modality capabilities beyond monoclonal antibodies, all at once. In hindsight, the long-term asset left from this phase was customers' trust in its process scale-up, quality systems, and ability to deliver on timelines, not a few factory buildings. The CDMO business has never been about lab showmanship; whether back-end programs can be retained depends on the reputation built from small front-end programs.

The second phase was a "boom-era expansion and capital-market peak-optimism period," roughly 2020 to 2021. Global biopharma funding was active and the pandemic pushed the importance of biomanufacturing to the fore, and WuXi Biologics used this wave to treat the capital markets as a capacity-expansion tool. The annual report disclosed that the company completed its fourth placement in February 2021 at a placement price of HK$112, netting about RMB 10.899 billion for existing-business expansion, and the 2025 annual report still shows that the share-price hurdle for the 2021 global partner plan had once been set at HK$97.8. In this phase the company chose to "trade equity for time at high valuations," buying the next few years of capacity in advance, rather than "conservatively harvesting profits." This capital allocation looked aggressive at the time, but it explains why the company was able to release operating leverage quickly when profits recovered in 2025.

The third phase was a "post-pandemic structural reset and organizational re-segmentation period," corresponding to 2022 to 2024. Two changes here mattered most. First, after pandemic-related business ebbed, the revenue mix began returning to more normal non-COVID biologics programs; second, the ADC and broader bioconjugate CRDMO business was gradually built into a standalone platform, with WuXi XDC ultimately listing separately in November 2023. For investors in 02269.HK, this step expressed high-complexity modality capabilities through clearer organizational boundaries while adding a new segment dimension to the parent's consolidated statements, rather than simply telling a new story. The market began to realize at this point that WuXi Biologics is a large system of "core platform plus new modalities plus global capacity," not a linear growth model, and the difficulty of understanding it rose accordingly.

The fourth phase is a "coexistence of manufacturing delivery and geopolitical discount period," extending from 2025 to the research reference date. In 2025 the company's financial results looked very much like a back-end manufacturing platform beginning to mature: revenue up, gross margin up, cash flow up, borrowings down, and single-customer concentration down. By the end of April 2026, management further disclosed 69 newly added integrated programs, two-thirds of which came from the U.S. and Europe; late-stage programs rose to 78, commercial programs remained at 25, customer retention stayed above 95%, and each of the top three manufacturing programs was expected to contribute over USD 100 million in revenue in 2026. The fundamental tempo is accelerating. Yet at the same time the policy environment suddenly issued a new reminder: on June 8, 2026, the U.S. Department of Defense added WuXi AppTec to the 1260H list, and while WuXi Biologics was not named, its potential relationship with the U.S. federal supply chain was once again repriced by the market. The pivot here is that pricing power partly shifted back from management into Washington's hands, rather than any change at the operating level.

Looking back at the key inflection points, four matter most to today. First, choosing a full-process platform rather than just a CRO or just a CMO at its 2010 founding, which determined that the company could later capture the back-end manufacturing dividend through its program funnel. Second, rapid globalization after the 2017 IPO, which means it is today not just China capacity but a network spanning China, the U.S., Germany, and Ireland and expanding toward Singapore. Third, raising capital to expand capacity at high valuations in 2021, which laid the capacity foundation for the later profit recovery. Fourth, the U.S. policy changes around BIOSECURE and 1260H over 2023-2026, which turned the "geopolitical discount" from market sentiment into the primary pricing variable. The first three points shaped what kind of company it became, and the last point determines what price the market is willing to give it.

Financial Review

The main thread in WuXi Biologics' financials over the past few years is that the revenue mix has gradually shifted from front-end R&D and pandemic disruption toward back-end manufacturing and complex-modality delivery, rather than simple "high revenue growth" or "revenue slowdown." 2025 company revenue was RMB 21.79 billion, of which pre-IND services were RMB 9.31 billion, a 42.8% share; early clinical services were RMB 2.64 billion, a 12.1% share; and Phase III and commercial manufacturing were RMB 9.46 billion, a 43.4% share. This set of figures is very important, because it shows the company is already a platform where back-end manufacturing revenue is close to half the total, no longer a CRO propping up its valuation with front-end program counts. From 2024 to 2025, the weakest segment happened to be early clinical services, down 30.8%; the strongest happened to be Phase III and commercial manufacturing, up 26.4%. This is not bad news; on the contrary, it is the platform model maturing: the most profitable, stickiest, and hardest-to-replace segment is starting to carry more weight.

The margin improvement comes from the same logic. In 2025 gross margin rose from 41.0% to 46.0%, and the annual report stated the reasons clearly: an improved business mix, higher capacity utilization, and efficiency gains from WBS and digitalization. There is not much room for "accounting cosmetics" here, because operating cash flow rose in step to RMB 6.34 billion, cash and time deposits rose to RMB 14.80 billion, while borrowings instead fell to RMB 1.04 billion. For a CXO, this combination of "better profit, even better cash, and still-declining leverage" is more persuasive than net profit alone. It shows the 2025 profit recovery came from genuine improvement in operating quality itself, neither a one-time subsidy nor dominated by fair-value gains.

Putting operating cash flow and expansion capex together completes the story. The company's operating cash flow for 2021-2025 was RMB 3.43 billion, 5.54 billion, 4.67 billion, 5.22 billion, and 6.34 billion respectively; over the same years, purchases of property and equipment were roughly RMB 6.51 billion, 5.87 billion, 4.05 billion, 3.93 billion, and 3.69 billion. In other words, this company has long been "putting cash back into capacity," not "unable to earn cash." Over the four years 2022-2025, the rough ratios of operating cash flow to net profit attributable to the parent were about 1.25x, 1.37x, 1.55x, and 1.29x, so the ability to convert profit into cash is actually decent; what truly held down free cash flow was the global biologics capacity build-out. This is critical for valuation: on a headline P/E basis the company looks like a mid-valuation growth stock, but on an owner-earnings basis, because much of the capex is fundamentally expansionary, the actual "distributable profit" is not severely overstated.

The balance sheet, in turn, gives the company an important cushion. At the end of 2025, total assets were RMB 63.697 billion, total liabilities RMB 10.657 billion, and equity RMB 53.039 billion; cash, bank deposits, and time deposits totaled RMB 14.801 billion, borrowings RMB 1.043 billion, and lease liabilities RMB 2.061 billion. On a basis that does not treat lease liabilities entirely as financial debt, the company is clearly net cash; even counting lease liabilities, financial pressure is far from tight. For a CRDMO still building global capacity and still needing to handle policy tail risk, this matters a great deal: it has enough capital-structure buffer to absorb program delays, slower order tempo, or customer caution amid policy maneuvering.

Another change that is easily overlooked but very important is that customer concentration is declining. The 2025 annual report disclosed that no single customer contributed more than 10% of total revenue that year, whereas in 2024 one customer still contributed RMB 2.065 billion, more than 10%. At the same time, the top-five customers' revenue share fell from 29.1% to 26.1%, and the top-ten customers' share fell from 41.7% to 37.6%. This shows two things: first, the company's growth no longer depends on a very small number of large orders; and second, in an environment of rising policy noise, customer and program diversification is itself a buffer. It cannot eliminate U.S. risk, but it can lower the probability that "one customer's decision change rewrites the whole year's profit."

Bringing the financial review up to today, what investors should most remember is that this company has already moved from a "burn capital for scale" stage to a "scale begins to repair profit in turn" stage, not some single quarter's EPS. The 2025 operating results show that operating leverage has emerged, and for 2026 management has given revenue growth guidance of 13%-17%, explicitly noting that this already includes about 300 basis points of FX headwind; on a constant-currency basis, that is equivalent to 16%-20% growth. For a CRDMO with net cash, a thick accumulation of back-end programs, and no clear signs of customer attrition, this is a posture of continuing to push toward back-end delivery, not a defensive posture. The question has always been whether this set of financial delivery can land ahead of policy risk, not whether the financials will deteriorate.

Share Price and Valuation History

WuXi Biologics' capital-market history can be roughly cut into three phases. The first phase ran from the IPO through the boom, an era of ample global liquidity, when the market priced it as a scarce biologics platform and was willing to pay a very high growth premium for "full process plus globalization plus high growth." The second phase was 2022-2024, when pandemic-related disruption faded, biotech funding slowed, and the expansion cycle entered a low-free-cash-flow stage before the harvest, and the market began to mark down its linear growth expectations. The third phase is the current one: financials have clearly recovered, but the valuation has not returned to the past, because the discount rate now carries an extra item called "policy uncertainty."

If you only look at today, WuXi Biologics' valuation is moderate. At the 2026-06-12 close of HK$30.50, 2025 net profit attributable to the parent of RMB 4.908 billion, and a conversion of 1 RMB = 1.1564 HKD, trailing P/E is roughly 22.3x; on a 2025 revenue basis, the price-to-sales ratio is roughly 5.0x. Placed within pharma outsourcing, this level is not cheap, but it is also far from bubble territory. The real shift is in cross-comparison: among large biologics manufacturing platforms, Samsung Biologics trades at roughly 29.9x P/E and Lonza at roughly 37.9x; among the China CXO reference companies, Pharmaron is roughly 23x and Asymchem roughly 36x. What the market gives WuXi Biologics is a blended valuation "between China CXOs and global high-end biomanufacturing," not a "low-quality asset discount."

This also means that changes in WuXi Biologics' valuation center can no longer be explained by the company alone. At the high valuation of 2021, the market believed that "every molecule could be drawn into the platform"; in 2026 the market cares more about "which molecules will ultimately be blocked at the door by policy." Commercial quality is no worse than at the peak, and many metrics are in fact more mature; the problem lies in the rise of the risk premium. Without a complete historical time-series database, I will not force a precise historical percentile here; but the qualitative judgment is clear: the current valuation is significantly below the boom-era expansion phase and closer to a maturing platform with improving cash flow, rather than a long-duration growth stock supported by unlimited far-future growth.

Business Model and Moat

WuXi Biologics' real commercial machine is built on a fact that is rarely spelled out: front-end R&D services are the customer-acquisition move to win back-end manufacturing rights, not the endpoint. The company wrote "follow the molecule" into its prospectus back in 2017; by 2025-2026, this model had become a string of very hard operating metrics: 74 Phase III programs and 25 commercial programs at year-end, updated to 78 late-stage and 25 CMO programs by the end of April 2026, customer retention above 95%, and each of the top three manufacturing programs expected to contribute over USD 100 million in revenue in 2026. For a biologics outsourcing company, this matters more than simply the number of newly signed programs, because the money is always made after a program moves back: process validation, PPQ, scale-up manufacturing, and ongoing supply.

Looking at the revenue mix, by 2025 the company already had both a front-end funnel and back-end delivery, two legs to stand on. Pre-IND services of RMB 9.31 billion are the platform entry; Phase III and commercial manufacturing of RMB 9.46 billion are the profit center; the decline in early clinical services to RMB 2.64 billion shows programs moving toward the back, rather than stalling in the middle. By region, North America still accounts for 58.1%, Europe 23.1%, and China 12.3%. On a segment basis, of the group's 2025 external revenue, the biologics core platform was RMB 15.89 billion and XDC (ADCs and bioconjugates) was RMB 5.90 billion. Because this report studies the listed entity 02269.HK, all of these must be consolidated; but for the investment judgment, I treat XDC only as part of WuXi Biologics' platform complex-modality capability, not as a separately rated stock.

The cost structure determines why profit repairs quickly once revenue ramps. The annual report disclosed that costs consist mainly of direct labor, raw materials, and overhead such as manufacturing, testing, and depreciation. For a biologics CRDMO, the hardest things to compress are global GMP facilities, quality systems, and skilled process teams, not selling expenses. Once capacity sits idle, these costs drag the margin down badly; once commercial programs and PPQ move up, higher capacity utilization quickly amplifies profit. The 500-basis-point gross margin improvement in 2025 was essentially fixed costs being absorbed by higher-quality back-end revenue.

The moat that genuinely holds up for this company, in my view, has four main strands. The first is regulatory and process switching costs. Biologics are not small-molecule APIs; once a customer has sunk a molecule's cell line, process package, analytical methods, validation systems, and manufacturing history into one platform, switching suppliers later carries costs including time, revalidation, regulatory communication, and even commercial-supply risk. The second is platform scale and full-process capability. Its core is that discovery, development, and commercialization can all be completed within one system, which is what makes programs more likely to stay, rather than "a big factory is the moat." The third is complex-modality capability, especially bispecifics, multispecifics, and ADCs, whose process complexity is clearly higher than traditional mAbs. The fourth is the global dual-source and multi-site capacity network; as customers care more and more about geographic redundancy, this network has itself become a productive asset. The company's website discloses that it currently operates over 262,000L of cGMP drug-substance capacity across four countries (China, the U.S., Germany, and Ireland), to be expanded in 2026 to roughly 588,000L across five countries including Singapore.

But this company also has two moats that "are easily exaggerated in the pitch and must be discounted in reality." First, pure "China cost advantage" is no longer a solid moat, because customers now weigh not just cost but also supply-chain sovereignty and policy redundancy. Second, the real moat is the retention rate and monetization efficiency of programs moving back, not the program count itself. The good news for WuXi Biologics is that it is correcting both of these on its own: the 2026 business updates emphasize late-stage, CMO, retention, MOU depth, and the revenue contribution of the top three manufacturing programs, rather than the total program count. Management knows the capital markets no longer pay separately for "lots of programs."

On governance, WuXi Biologics' strengths and discount coexist. The strength is that founders and management still have fairly deep interest alignment: at the end of 2025, Ge Li, through controlled entities and concert-party arrangements, corresponded to a combined 12.34% equity interest, and CEO Chris Chen also holds a sizable personal interest. Capital allocation over the past few years has also had two sides: decisive new-share issuance to fund capacity at high valuations, and the start of buybacks at low valuations, with 60,539,500 shares repurchased in the first half of 2025 for about HK$1.111 billion. The discount lies in high organizational complexity, close ties to other WuXi-group platforms, and the fact that although the Deloitte reappointment resolution passed at the 2026 AGM, the share of votes against reached 28.62%, which at least shows some shareholders have reservations about governance or information transparency. It is not a red flag, but it is definitely a yellow light.

Industry and Cycle Analysis

WuXi Biologics operates in an outsourcing industry layered atop a "biologics innovation cycle" and a "global supply-chain rebalancing," not ordinary manufacturing. The largest profit pool in this industry is in back-end manufacturing, not front-end experimentation. The reason is simple: front-end R&D services can help customers enter the process, but what is truly sticky, high-switching-cost, and able to sink years of cash flow is late-stage clinical and commercial supply. WuXi Biologics' back-end revenue already reached 43.4% in 2025, which is the watershed between it and an ordinary CRO. What customers are truly willing to pay a high price for is "can you get the IND on time, complete PPQ on time, and supply on time," not a handful of experiments.

The industry's growth drivers are also more complex than they appear on the surface. On the demand side, aging populations, the rising burden of obesity and immune diseases, and the rapid development of complex modalities are all pushing up the number and complexity of biologics; on the supply side, big pharma and biotech are increasingly unwilling to rebuild a production line for every new molecule themselves, and so outsource more process development and manufacturing to platforms with scale. In its 2025 annual report, WuXi Biologics explicitly named complex modalities, especially bispecifics, multispecifics, and complex ADCs, as one of the long-term demand drivers; and the 2026 update further shows that, among newly signed programs, bispecifics and multispecifics still grew over 50% year on year. This means the industry is migrating toward higher complexity, not simply recovering. The higher the complexity, the greater the platform's value.

In terms of cyclical characteristics, WuXi Biologics is layered with at least four cycles. The first is the global biotech funding cycle, which affects the count of the most front-end programs. The second is the biologics commercialization ramp cycle, which affects back-end capacity utilization and gross margin. The third is the capex cycle, which affects whether free cash flow looks "like a good business." The fourth is the policy cycle, especially U.S. security scrutiny of China's bio supply chain. Over the past few years the most fragile variable has actually been how much valuation the market is willing to give, not revenue. Because even if the company's fundamentals do not collapse, as long as BIOSECURE risk is re-amplified, most global investors will first demand a lower portfolio weight.

Policy and geopolitics are the core that this report cannot avoid. On December 18, 2025, the President signed the FY2026 NDAA, bringing into effect the provisions commonly known as the BIOSECURE Act. The law itself does not directly name WuXi Biologics; instead, it requires OMB to publish a list of "biotechnology companies of concern" within one year of the law taking effect, that is, before December 18, 2026, with the proposed list led by the Department of Defense in coordination with multiple agencies. The law also stipulates that listed companies have a notice, response, and review procedure before public disclosure, and OMB will only finalize and publish after completing the review. In other words, as of 2026-06-12, WuXi Biologics' policy risk is real, but it is still not a restriction target on which the hammer has fallen.

What truly raised this risk by a level was the U.S. Department of Defense's June 8, 2026 update to the 1260H list, which added WuXi AppTec. What appears clearly on the official list is WuXi AppTec; WuXi Biologics does not appear on this list. Ropes & Gray's legal analysis on June 10 specifically noted that WuXi Biologics was not named on the list and would not be automatically implicated by WuXi AppTec's listing, because the two are not parent-subsidiary or successor entities of each other. This fact is critical. It rewrites WuXi Biologics' risk from "already landed directly" into a suspended risk that is "highly correlated, not yet landed, but cannot be ignored." For investors, this is harder to price than "already sanctioned," because it does not constitute a simple one-time loss but a long-term rise in the discount rate.

At the industry-structure level, the most important thread going forward is whether "non-China sovereign secure capacity" will continue to command a higher premium. What Samsung Biologics and Lonza enjoy today is no longer just a scale premium but customers' preference on sovereignty, security, and geographic redundancy. WuXi Biologics may not lose on technology, program funnel, or process, but it is naturally at a disadvantage on the political environment. What the market now presses on is: after the U.S. federal funding system and big pharma supply-chain governance tighten further, how many molecules will still be willing to hand the last mile to it rather than doubt whether it can manufacture at all. This question will not be answered by a single set of results over the next year, but by where programs flow.

Peer Comparison

If you place WuXi Biologics in its real competitive environment, it occupies a very particular niche: it is neither priced mainly through a China R&D-and-manufacturing outsourcing risk discount like Pharmaron and Asymchem, nor viewed almost entirely as a "sovereign-friendly" global manufacturing platform like Samsung Biologics and Lonza. It is more like an intersection of two valuation frameworks: commercially it is increasingly close to a global biologics manufacturing platform, yet the capital markets still retain a clear China geopolitical discount. This dislocation is precisely the core source of WuXi Biologics' investment judgment.

Compared with Samsung Biologics, WuXi Biologics is more like a "platform CRDMO with a deeper program funnel," while Samsung Biologics is more like a "giant, sovereign-secure, pure back-end-manufacturing industrial platform with stronger scale." Samsung Biologics' advantage is that customers will not reassess its compliance boundary because of Washington scrutiny, and the market is willing to pay a higher P/E for its premium on ultra-large-scale commercial capacity and sovereign-security attributes. WuXi Biologics' advantage lies in the depth of its front-to-back integrated platform and its program coverage and conversion capability in complex modalities such as bispecifics, multispecifics, and ADCs. Put simply, Samsung is more about "perfecting back-end manufacturing," while WuXi is more about "connecting front and back ends and then capturing back-end delivery." The former more easily gains valuation stability, while the latter has greater elasticity in favorable conditions.

Compared with Lonza, the difference is more concentrated in pricing power and the political environment. Lonza's premium today comes from both execution and the credibility of "Swiss/European capacity." Customers who choose Lonza are buying not just process but a supply-chain coordinate that will not suddenly be drawn into the center of U.S. legislative controversy. WuXi Biologics is quite competitive on commercial speed and program funnel, and the 2026 update also shows two-thirds of new programs still come from the U.S. and Europe; but in the eyes of boards, procurement, and compliance departments, whether these molecules need a second source prepared in the future clearly has a different answer than Lonza. It is exactly for this reason that Lonza can maintain a P/E near 38x while WuXi Biologics can only hover around 22x.

Putting Pharmaron and Asymchem into the comparison framework makes the conclusion more interesting. They are not WuXi Biologics' direct rivals in back-end biologics manufacturing, but they are the reference investors actually use to price the China pharma-outsourcing sector. In other words, they do not determine why WuXi Biologics' customers choose it, but they influence whether a fund manager gives it 20x or 30x. As of the research reference date, Pharmaron is roughly 23x P/E and Asymchem roughly 36x P/E; WuXi Biologics is roughly 22x, already closer to the lower bound of the "risk-discount valuation" of domestic CXOs than the upper end of the valuation range of global biologics manufacturing platforms. This is why I say it is now in the middle of a valuation re-rating, rather than pure high growth.

WuXi AppTec is another kind of comparison: it is not a consolidated investment target of WuXi Biologics, but it is the most direct reference for the transmission of geopolitical risk. What entered the 1260H list on June 8, 2026 was WuXi AppTec, not WuXi Biologics; but the capital markets will not cleanly cut along legal terms, and will first discount based on brand, supply-chain association, and policy sentiment. Therefore, WuXi AppTec being formally named affects WuXi Biologics more like a "valuation alarm" than an "immediate shutdown order." This also explains why WuXi Biologics could still win U.S. and European programs in its 2026 business update without that meaning the share price could regain the kind of valuation recovery seen by non-China peers.

In terms of niche, WuXi Biologics remains one of the leaders in global biologics outsourcing, but not a leader with unconditional pricing power. What it truly fills is the gap of a "full-process industrialization platform for complex biologics," and what it most directly takes is the profit pool of traditional big pharma's in-house pilot lines and some outsourcing platforms; the two most likely to take its profit pool come from two directions: one is sovereign-friendly large platforms such as Samsung and Lonza, and the other is customers' stronger internal dual-source and multi-source strategies. The most frightening near-term risk is the politicization of the supply chain, not technological substitution.

Current Fundamentals and Bull-Bear Divergence

The conclusion first: the latest public information shows that WuXi Biologics' fundamentals are improving, and the improvement is not visible only in the income statement. 2025 revenue grew 16.7% year on year, gross profit grew 30.9%, gross margin rose to 46.0%, net profit attributable to the parent grew 46.3%, and operating cash flow was RMB 6.34 billion; management guided 2026 revenue growth of 13%-17%, explaining that this already includes about 300 basis points of FX headwind, equivalent to 16%-20% growth on a constant-currency basis. By the end of April 2026, the company further updated 69 newly added integrated programs, over 95% customer retention, 78 late-stage programs, and 25 commercial programs. Linking these data together, the operating side has returned to a deliverable range, not a "weak recovery."

What is the market trading right now? I think the market is mainly trading three things. First, manufacturing delivery. The 2026 update disclosed that each of the top three manufacturing programs will contribute over USD 100 million in revenue, showing the revenue center is moving toward the high-quality back end. Second, the margin from complex modalities. Newly signed bispecific and multispecific programs grew over 50% year on year, and such programs are more complex in development, analytics, and scale-up, and usually harder to replace. Third, whether the policy discount needs to be raised further. This variable was put back on the table by investors after WuXi AppTec entered 1260H on June 8. In other words, the share price is trading "whether the recovery is worth being discounted by policy risk," not "whether WuXi Biologics has recovered."

The bulls' chain of evidence is actually quite solid. The strongest link is that orders and programs have not shown a "policy-panic rupture." If U.S. and European customers were truly canceling orders en masse, the company should not have been able to add 69 programs in the first four months of 2026, two-thirds of them from the U.S. and Europe; it should not have been able to maintain over 95% customer retention; and it should not have been able to disclose an MOU with a global big pharma covering 16 programs and a potential 10-year, USD 5 billion scale. The second piece of bull evidence is the high quality of the profit recovery. The 2025 gross-margin improvement happened in step with rising operating cash flow, showing the improvement came from utilization and business mix, not pure financial maneuvering. The third piece of evidence is declining customer concentration, with no single customer exceeding 10% in 2025. This means the company looks more like a platform-wide recovery than being "lifted up" by one or two large orders.

The bears' evidence is equally concrete. The first bear logic is the geographic exposure sitting right there: in 2025 North America accounted for 58.1% of revenue, and the U.S. remains the largest revenue pool. As long as the BIOSECURE/BCC list remains unresolved, the company will struggle to obtain a fully normal risk discount rate. The second is that part of the order quality is naturally not that "hard." 2025 total backlog was USD 23.7 billion, of which service backlog was USD 11.5 billion and potential milestones USD 12.2 billion; the latter is an elastic item tied to program advancement and regulatory progress, not already-locked cash flow. The third is that sister-company read-through risk has escalated. WuXi AppTec entering 1260H at least shows that Washington has begun genuinely writing individual companies into lists, rather than just using "WuXi" as an abstract target. For WuXi Biologics, this will not immediately rewrite revenue, but it will change how often customer boards and legal teams ask about a second source.

This also explains why I describe the current state as "fundamentals stronger than the share price, while the share price is not wildly wrong." WuXi Biologics is not in operating collapse now, so it cannot be treated as a value trap; but its policy risk has not disappeared either, so the 2025 results recovery cannot be linearly extrapolated directly into a valuation recovery. What the market truly needs to see is not just continued growth in 2026, but whether the growth can pass through listing risk and remain within the U.S. and European customer base. As of 2026-06-12, there is no final public document with this answer.

Valuation Analysis

WuXi Biologics' valuation must first see through cash flow before discussing multiples. Because this company has long been building capacity globally, free cash flow can look poor for a time, but that does not mean profit is illusory. According to the annual report cash-flow statement, operating cash flow for 2022-2025 was RMB 5.54 billion, 4.67 billion, 5.22 billion, and 6.34 billion respectively; over the same years, purchases of property and equipment were roughly RMB 5.87 billion, 4.05 billion, 3.93 billion, and 3.69 billion. For a biologics CRDMO still expanding globally, the bulk of this capex is clearly expansionary rather than purely maintenance. The 2025 headline trailing P/E was roughly 22.3x as of the research reference date; on a more conservative "owner-earnings" basis, considering that maintenance capex is very likely only part of total capex, the valuation on actual owner earnings is not much more expensive than the headline P/E. This is because the company's profit-to-cash conversion is in fact decent, and what truly holds down shareholder returns is the continued reinvestment into the capacity network.

On historical valuation, I will not force a precise percentile, because this round did not pull a complete five-year daily-frequency valuation series. But the qualitative judgment is clear: the current roughly 22x trailing P/E is clearly below the long-duration growth premium the market was willing to give in the boom-era expansion phase; on the other hand, it is also not the extreme discount level of the 2024 policy panic. That is, the market has acknowledged the operating recovery but has not acknowledged that the geopolitical discount should disappear. The change in the valuation center comes more from a rising discount rate than from business-model decay.

Peer valuations make the point more clearly. Around the research reference date, Samsung Biologics trades at roughly 29.9x P/E, Lonza roughly 37.9x, Pharmaron roughly 23.2x, and Asymchem roughly 36.3x; WuXi Biologics is roughly 22.3x. This position shows the market has neither priced WuXi Biologics as a global risk-free biomanufacturing platform nor treated it as the worst China CXO. It sits between two sets of references: its commercial substance is closer to the global large platforms, while its valuation discount is closer to the China outsourcing companies. Whether this discount widens or narrows in the future depends not on whether revenue is 2 percentage points higher in a single quarter, but on whether the policy boundary becomes clearer.

Scenario Valuation

The table below is a valuation framework built on public information and research assumptions, not investment advice. Prices are uniformly in HKD per share, converted at the 2026-06-12 CNY/HKD rate.

Within this framework, the price ranges I give are: conservative scenario HK$20-24, base scenario HK$28-35, optimistic scenario HK$38-48. The core here is that the market is already near the lower half of the base range, which shows WuXi Biologics is not cheap enough to ignore geopolitical risk, rather than some decimal point.

Expectations Gap Analysis

The expectations the market currently implies are actually more conservative than they appear on the surface. The share price has not returned to the global biologics platform valuation range on the back of 2025 profit elasticity, which shows the market assumes it will continue to pay a geopolitical discount in the future. What could truly create an expectations gap is three harder metrics, not whether revenue is a point higher or lower: first, whether U.S. and European programs keep increasing; second, whether late-stage/CMO and PPQ keep advancing on plan; third, whether policy documents keep staying at "suspended risk," or begin to land on the company entity itself. The next event that will truly change both sides' judgment may not be results, but any document related to OMB/BCC, the U.S. federal supply-chain definition, or a major customer's public procurement policy.

Margin-of-Safety Review

At the current HK$30.50, the share price is a premium relative to the conservative-scenario value, not a discount, so the strict margin of safety is zero. The most fragile assumption in the conservative scenario is the valuation multiple, not revenue: as long as the market keeps demanding a policy discount, even if earnings growth can still hold, the base value will be held down. If you apply a 30% haircut to the roughly 20x multiple in the base scenario, base value quickly falls to roughly HK$22-24. If earnings see zero growth over the next three years and the company pays no dividend, then under high capex the annualized shareholder return will not look good, more like 0% to low single digits than an investment with a thick safety cushion. My independent conclusion is: there is no margin of safety. WuXi Biologics is more like "a good company at merely an ordinary price right now," not "a good company given a bad-weather price today."

Risk Analysis

The risk that most demands serious treatment, first, is formal listing risk. I assign probability medium and impact high. The reason is that the legal procedure is already built, and the Department of Defense added WuXi AppTec to 1260H on June 8, 2026, proving Washington's toolbox is already moving, rather than the company being restricted as of 2026-06-12. The observable indicators truly worth watching are whether OMB publishes a draft BCC list, whether there is any notice directly related to the company entity, and whether large multinational pharma publicly adjusts supply-chain compliance policy, not social-media rumors. Once it happens, the transmission path is clear: new orders slow first, the conversion rate of back-end manufacturing falls, the valuation multiple gets killed first, and profit comes later.

The second risk is "orders do not drop, but order quality deteriorates." Probability medium, impact also high. Many investors only watch the count of new programs, but what a platform like WuXi Biologics fears most is actually a declining share of programs moving to the back end, not a few fewer front-end programs. If customers, for compliance and board-governance needs, demand more dual-source or multi-source arrangements before late-stage or commercialization, then front-end programs will still be signed, but mid-to-back-end contribution will be diverted. Observable indicators include late-stage/CMO program counts, PPQ completion progress, the revenue contribution of the top three manufacturing programs, and whether gross margin can still hold steady around 44%-46%. As long as back-end conversion efficiency declines, WuXi Biologics' operating leverage will first lose its most powerful fulcrum.

The third risk is that the complex-modality dividend comes in below expectations. Probability medium, impact medium-high. The reason the market is willing to give WuXi Biologics a somewhat higher valuation than an ordinary China CRO today is precisely the high value-add and high retention from a rising share of complex modalities such as bispecifics, multispecifics, and ADCs. If this demand grows less than expected, or competitors quickly close the capability gap, WuXi Biologics' gross-margin improvement may be shorter than the market thinks. Observable indicators are the year-on-year growth of newly signed bi-/multi-specific programs, their corresponding back-end advancement, and the share of complex modalities in late-stage and CMO. The transmission of this risk will not be as violent as policy, but it will gradually lower medium-term ROIC and the valuation ceiling.

The fourth risk is a three-currency mismatch and receivables quality. Probability medium, impact medium. WuXi Biologics' Hong Kong shares are quoted in HKD, its reporting currency is RMB, and backlog is in USD, while revenue is also heavily from North America and Europe. Management has already explicitly flagged that the 2026 guidance includes about 300 basis points of FX headwind; the annual report also shows ECL impairment losses increasing from RMB 152 million in 2024 to RMB 205 million in 2025, mainly due to receivables expansion driven by revenue growth. As long as the company keeps taking orders globally and settling across currencies, this kind of financial volatility will recur. It will not destroy the company on its own, but it will make the valuation story harder to keep "pure."

The fifth risk is governance and organizational complexity. Probability low to medium, impact medium. WuXi Biologics is not a company with governance out of control, but it does have complex ties among WuXi-group platforms, subsidiary spin-off listings affecting the consolidation scope, and signs that shareholders have reservations about governance details. The 28.62% of votes against the auditor reappointment resolution at the 2026 AGM is a signal that cannot be ignored. For long-term investors, this kind of risk generally does not show up in a single quarter's profit, but in the valuation failing to rise when risk appetite increases.

Catalysts and Tracking Indicators

The most important positive catalyst is "proving the good results can be sustained," not "putting out another good result." There are three most powerful positive catalysts. First, late-stage, CMO, PPQ, and the top three manufacturing programs continuing to deliver on plan in 2026, which would make the market more willing to treat it as a mature manufacturing platform rather than a front-end program platform. Second, if the execution boundary of OMB/BIOSECURE becomes clearer within 2026 and WuXi Biologics continues to stay off the formal restriction list, the discount will naturally narrow. Third, U.S. and European customers continuing to contribute new programs, especially deeper big-pharma collaboration being further disclosed, which would form the most direct rebuttal to the bear narrative that "customers are fleeing."

The negative catalysts are clearer still. Any 1260H/BCC naming directly related to the WuXi Biologics entity is the No. 1 risk; next is revenue not dropping but gross margin dropping first, which usually means a problem with back-end mix or utilization; next is a clear slowdown in North American revenue and newly signed programs, where even if the company verbally stresses the pipeline is still steady, the market will cut the valuation first. Finally, if operating cash flow again significantly lags net profit, or ECL, receivables, or days-sales-outstanding expand abnormally, that too would weaken the key argument that "the profit recovery is high quality."

Tracking Dashboard

Among these indicators, the four most worth prioritizing are: late-stage/CMO count, PPQ tempo, gross margin, and policy documents. The first two determine order quality, the third determines earnings delivery, and the fourth determines how many multiples the market is willing to give. The tracking sources are mainly the company's annual report, interim report, business updates, and U.S. official documents; truly effective research strings these indicators into a continuous diagnostic chart, rather than rewriting the story at every results release.

Cross-Sectional and Longitudinal Synthesis

Longitudinally, what WuXi Biologics has truly proven all along is the ability to turn biologics outsourcing into a platform industry, not single-point scientific capability. From its 2010 founding, it never defined itself as the supplier of one lab or one process step, but instead made "carrying a molecule all the way through" its business model. After listing, the company used capital-market money during the high-valuation phase to buy time, capacity, and global footprint; over the following years, although it went through a post-pandemic reset, a weakening funding cycle, and policy scrutiny, the 2025 results show this heavy capital investment was not running in place. Today its profit elasticity, cash-flow quality, and back-end program share already look more like a maturing biologics platform. Of course there is an era dividend in this success, especially rising global biologics penetration and a higher big-pharma outsourcing ratio; but more important is management's grip on the platform's tempo: when to grab programs, when to grab capacity, when to spin out a new-modality platform, and when to buy back.

Cross-sectionally, WuXi Biologics' real advantage is in "depth," not in "cheapness." Samsung Biologics and Lonza are stronger in back-end sovereign security and pure-manufacturing premium; domestic CXOs are more easily lumped by the market into a uniform China risk basket; WuXi Biologics' unique position is that it has the platform depth of globalization, integration, and complex modalities, yet cannot fully escape the China geopolitical discount. This is both its advantage and its valuation ceiling. The advantage is that once the policy boundary becomes slightly clearer, the elasticity of valuation repair will be large; the ceiling is that when the boundary is unclear, the market would rather first buy the more expensive Samsung and Lonza than give WuXi Biologics the same certainty multiple.

The current valuation looks more like rewarding the manufacturing delivery it has already proven, without prepaying for a future in which "policy risk automatically disappears." At roughly 22x trailing P/E as of the research reference date, the price is neither cheap enough to say "buy blindly" nor high enough to say "stay away." Where I think the market most misjudges it is that many people imagine the risk as a binary event: as if not being listed means all is well and being listed means total paralysis. Reality is more like a continuum. Even if it is not formally listed in the future, the company may long bear a discount from customers' second-supplier strategies; yet even if it is truly named in the future, the impact may not immediately spread to all commercial customers. The hardest thing in investing is precisely this kind of "non-linear, non-synchronous" risk.

The most critical variable over the next year is whether the policy boundary and manufacturing delivery can keep coexisting; the most critical variable over the next three years is whether U.S. and European customers keep leaving back-end programs with it, and whether complex modalities keep lifting retention and margins; the most critical variable over the next five years is whether WuXi Biologics can truly re-rate itself from "China biologics outsourcing leader" into "global biologics platform." Among these three layers of variables, the first is the soonest to be validated, which is also why my attitude toward the current price will not be too aggressive. For a new buyer, the margin of safety is not yet thick enough, rather than there being no value.

Bull Case

• The 2025 profit recovery is high quality, with gross margin lifting to 46.0% and operating cash flow rising in step to RMB 6.34 billion, showing the improvement came from operations rather than financial window-dressing.

• Phase III and commercial manufacturing revenue already reaches 43.4% of the total, and the platform is starting to truly capture the back-end manufacturing dividend.

• By the end of April 2026 it still added 69 integrated programs, two-thirds from the U.S. and Europe, with customer retention still above 95%, showing orders have not seen systematic departure.

• Complex modalities are accelerating, with newly signed bispecific and multispecific programs growing over 50% year on year; such programs are more complex, have higher retention, and have more resilient gross margins.

• The balance sheet is strong, with cash and time deposits of RMB 14.80 billion and borrowings of only RMB 1.04 billion at the end of 2025, enough to withstand capacity expansion and policy disturbance.

Bear Case

• U.S. policy risk remains a suspended, high-impact variable; the legal framework has taken effect, while the OMB list still awaits publication before 2026-12-18.

• 58.1% of 2025 revenue still came from North America, with the largest profit pool located precisely in the highest-risk geography.

• USD 12.2 billion of the backlog is potential milestones, not equivalent to rigid revenue; delivery quality cannot simply be linearly extrapolated from total backlog.

• The current roughly 22x trailing P/E does not constitute a clear "mispricing," and the margin of safety is thin for new money.

• WuXi AppTec was added to 1260H in June 2026, showing read-through risk is no longer a far-future hypothesis but a present source of valuation pressure.

Pre-mortem

If this investment loses 50% three years from now, one of the most likely scripts is: from the end of 2026 into 2027, WuXi Biologics is formally added to an OMB/BIOSECURE-related list, several large U.S. pharma companies require in new-program tenders that all federal or federally funded programs must shift to non-China supply chains, the company's North American new programs slow, late-stage program advancement decelerates, gross margin falls from 46% back to 40%-42%, and the valuation the market is willing to pay compresses from 22x to 14-16x. At that point, even if revenue does not fall off a cliff, the share price could still draw down 40%-50%. In this script, what hurts most is the growth story losing its certainty, not a one-time plunge in revenue.

Another more "operational" loss script is: policy does not land directly, but customer de-risking lands first. From 2027, more U.S. and European customers keep front-end collaboration but split back-end GMP and commercial manufacturing to a second supplier; WuXi Biologics' new program count still looks respectable on the surface, but the conversion speed of late-stage/CMO declines, the top three manufacturing programs grow below expectations, newly built capacity runs at low utilization, and operating leverage fails. The market had expected it to move closer to a "Samsung/Lonza-ized" manufacturing platform, but it gets repriced back to a China CXO "with only front-end elasticity and insufficient back-end elasticity." Such a script need not require formal sanctions, yet it is equally enough to halve the share price.

This company is worth owning, but even more worth owning at a chosen price. WuXi Biologics has already proven it can turn a front-end program library into back-end manufacturing revenue, and has already proven its financial recovery is not an accounting illusion. Data from 2025 and the first four months of 2026 both show the company has not seen the "mass customer retreat" outsiders most fear. Judging by operations alone, this looks more like a maturing platform moving from an expansion phase into a delivery phase.

The problem is that a stock is not bought on operations alone. As of 2026-06-12, what investors must bear is a policy tail risk with no final document yet, not merely industry-cycle fluctuation. After WuXi AppTec was added to 1260H, the subjective probability of this risk can hardly be treated as a fringe event any longer. It is precisely for this reason that I am unwilling to define it as "cheap" at the current price, even though I acknowledge its commercial quality is stronger than many peers in the sector. A more accurate statement is: this is a company worth tracking long term, where existing holders can keep holding and watching delivery, but new money is best off waiting for a thicker margin of safety.

If two kinds of changes appear over the next 6-12 months, I would be more willing to raise my level of conviction. The first is a clearer policy boundary, especially the OMB/BCC execution definition not including WuXi Biologics, or no systematic change in customers' public procurement behavior. The second is operations continuing to move toward the back end, with late-stage, PPQ, commercial programs, and top-three manufacturing program revenue continuing to deliver, and gross margin holding 44%-46%. Conversely, as long as North American newly signed programs slow, back-end conversion loses pace, or the company entity sees any material listing progress, the core judgment of this report would need to be rewritten.

【Company Profile Scores】

• Fundamental quality: High

• Growth: Medium

• Moat: Medium

• Financial robustness: Strong

• Management credibility: Medium

• Valuation attractiveness: Medium

• Risk level: High

• Suitable investor type: Not suitable for ordinary investors

【Investment Rating】

• Rating: Hold

• One-line investment thesis: Manufacturing delivery has been validated, but listing risk is not yet resolved, and the current price still has a thin margin of safety.

• Three-tier price signals: Ideal buy price: HK$20-24

• Acceptable holding price: HK$28-35

• Clearly overvalued price: above HK$38

• Current price classification: Acceptable to hold

• Whether to wait for a better price: Yes. The more ideal trigger range is HK$20-24, on the premise that the company entity sees no new material adverse policy progress; the opportunity cost of waiting is that if the policy boundary clarifies first, the valuation may repair directly without offering a low price.

• Target holding period: 1-3 years

• Expected annualized return: conservative about -15% to -25%; base about 0% to +15%; optimistic about +25% to +55%

• Maximum loss risk: if the company entity is formally added to a relevant list and triggers material dual-source switching by U.S. and European customers, a 40%-50% decline within 12-24 months would be within reason.

• Signals that trigger reassessment: If the company entity receives a formal naming or notice related to BCC/1260H;

• If the next public business update shows late-stage program count no longer growing or commercial program count declining;

• If gross margin falls below 42% and persists for two reporting periods;

• If North American revenue turns negative year on year and new programs are clearly weaker than U.S. and European peers;

• If operating cash flow consecutively lags net profit attributable to the parent, and receivables impairment keeps rising.

【Ideal/Fair Buy Price】HK$20-24 Rationale: This corresponds to a risk-discount price of 16-18x P/E under the conservative scenario, able to provide a more tangible buffer for the policy tail risk.

【Valuation Range】

• current: 30.50 (as of the 2026-06-12 close)

• bear (conservative · ideal buy zone): [20, 24]

• base (fair · acceptable holding zone): [28, 35]

• bull (optimistic · above the clearly-overvalued line): [38, 48]

Key Data Tables

The table above comes from the company's 2025 annual report and cash-flow statement, reflecting three things happening at once: operating recovery, earnings quality, and the balance sheet.

The most important message in this table is: the company has the ability to generate cash, it just keeps putting cash back into capacity over the long term. From 2024-2025, capex declines while operating cash flow keeps rising, and platform operating leverage begins to show.

In the table, WuXi Biologics' valuation is calculated independently using the report's reference-date close and issued share count; the other companies use public market data near the research reference date. You can clearly see that WuXi Biologics' commercial form is closer to the global large platforms, while its valuation is closer to the China CXOs.

Research Uncertainties

• I did not pull WuXi Biologics' complete long-term daily-frequency valuation series in this single search, so the "historical percentile" can only be a qualitative judgment, not a strict percentile point.

• The company does not separately disclose maintenance capex, so in the owner-earnings valuation I can only make a conservative inference based on the expansion tempo and asset network, and cannot precisely separate maintenance from expansion spending.

• WuXi Biologics had not been formally added to the BCC list as of 2026-06-12, and the true policy boundary awaits OMB's subsequent documents; this means the most critical risk variable itself is still unsettled.

• The company's public disclosure is mainly annual reports, interim reports, and business updates, lacking standard quarterly statements; therefore the analysis of the "most recent four quarters" can only be built on the annual and business-update cadence, not a complete quarterly breakdown.

• In the peer comparison, Samsung Biologics and Lonza are the closer operating references, while Pharmaron and Asymchem are more valuation references; they are not fully homogeneous and comparable, so the cross-sectional valuation conclusion should be read for direction, not treated as a mechanical score.

Reference Sources

• WuXi Biologics' 2025 annual report and financial statements are the first-hand source for this report on revenue mix, profitability, cash flow, the balance sheet, and customer concentration.

• WuXi Biologics' 2025 results presentation and May 2026 business update disclosed operating indicators such as new programs, late-stage/CMO, complex modalities, customer retention, and key 2026E manufacturing programs.

• The 2017 prospectus and IPO press releases, used to reconstruct the company's founding and IPO path.

• The 2021-2024 annual report cash-flow statements, used to fill in the operating cash flow and capex trajectory of the past several years.

• The 2026 annual general meeting voting results and buyback/share-capital announcements, used to determine the issued shares and governance observation points near the research reference date.

• The FY2026 NDAA/BIOSECURE legal framework, the OMB list deadline, and the announcement procedure, from the White House signing statement, the bill text, and legal analyses.

• The June 8, 2026 DoD 1260H updated list and the legal community's analysis of its impact, the key basis for this report's judgment of WuXi Biologics' policy-risk standing.

• The research-reference-date share price, RMB/HKD exchange rate, and peer valuation snapshot, from public market quote pages.

Other Tickers Mentioned in This Report

• 603259.SHG — WuXi AppTec; a WuXi-group small-molecule CRDMO, same group but separately listed, and also the direct reference for the June 2026 1260H event.

• 02268.HK — WuXi XDC; an ADC and bioconjugate CRDMO platform, an important observation object for the XDC segment and complex-modality capability within the 02269 consolidation scope.

• 207940.KRX — Samsung Biologics; a direct comparable reference for a large-scale global biologics manufacturing platform, used to compare the "sovereign-friendly" valuation premium.

• LONN.SWX — Lonza; a European biomanufacturing and CDMO benchmark, used to compare the valuation center of global high-end platforms.

• 300759.SHE — Pharmaron; a valuation reference for the China pharma-outsourcing sector, helping to identify the boundary of the "China CXO discount."

• 002821.SHE — Asymchem; a China CDMO valuation reference, used to compare which kind of asset WuXi Biologics' current valuation is closer to.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.